Randye Karmin, MD
Obstetrics & Gynecology · Miami, FLNPI 1467557546
Payments from drug & device makers
Across 69 payments — averaging $105.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$6K
- AbbVie$257
- Hologic Sales And Service, LLC$226
- Astellas Pharma US Inc$204
- Exact Sciences$91
- Sumitomo Pharma America, Inc.$70
- plus $387 from 12 others
What the payments were for
- Consulting fees$5,73579%
- Food & beverage$1,40719%
- Education$1122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 17 | $6,018 |
| AbbVie(2 entities) | 13 | $257 |
| Hologic Sales And Service, LLC | 6 | $226 |
| Astellas Pharma US Inc | 6 | $204 |
| Exact Sciences | 4 | $91 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
| Agile Therapeutics, Inc. | 3 | $68 |
| Meditrina | 1 | $42 |
| Coopersurgical, Inc. | 2 | $39 |
| Pfizer | 2 | $37 |
| Therapeuticsmd, Inc. | 2 | $36 |
| Millicent US Inc | 2 | $31 |
| Lupin Inc. | 2 | $30 |
| Mayne Pharma Commercial LLC | 2 | $26 |
| Myovant Sciences Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Evofem Biosciences, Inc. | 1 | $20 |
| Dysis Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Slynd$5,735
- NovaSure$143
- MYOSURE TISSUE REMOVAL DEVICE$143
How this compares
$7,254 in reported general payments places this provider in the 90th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol (Twice Weekly)Estradiol | 25 | $2,916 |
| Estradiol | 41 | $2,567 |
| ValacyclovirValacyclovir Hcl | 26 | $987 |
| ProgesteroneProgesterone, Micronized | 20 | $556 |
| Temazepam | 13 | $348 |
| Alprazolam | 12 | $231 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $157 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Miami
- Guillermo LievanoMiami$2.5M
- Victoria BedellMiami$1.4M
- Sarah BedellMiami$1.1M
- Luis LeyvaMiami$754K
- Joanna BedellMiami$575K
- Julio ArronteMiami$290K
- Beatrice HeckerMiami$172K
- Samuel LedermanLake Worth$13.4M
- Richard MyersJacksonville$2.7M
- Steven McCarusCelebration$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.